[ad_1] Biocon Ltd on Monday said its arm Biocon Pharma Ltd has received approval from the US health regulator for its generic version of Everolimus tablets for oral suspension used in the treatment of tuberous sclerosis complex, a rare genetic disease that causes non-cancerous tumors or lesions in different parts of the body. The approval…
[ad_1] Biocon Biologics, global subsidiary of Biocon Limited, informed on Thursday that the USFDA has classified its Drug Substance Facility in Bengaluru as Voluntary Action Indicated (VAI). “The U.S. Food and Drug Administration (FDA) CDER-OC, Office of Manufacturing Quality, has classified Biocon Biologics’ Drug Substance Facility at Biocon Campus, located in Bengaluru, Karnataka, as Voluntary…
[ad_1] Biocon Biologics Gets Health Canada Nod for Yesintek, a Biosimilar to Stelara We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok [ad_2] Source link
[ad_1] Biocon Ltd on Thursday said its arm Biocon Biologics Ltd has received an approval from Health Canada for chronic autoimmune conditions treatment medications Yesintek and Yesintek IV. The notice of compliance (NOC) granted by Health Canada is for Yesintek (ustekinumab injection) and Yesintek IV (ustekinumab for injection, solution for intravenous infusion), Biocon Ltd said…
[ad_1] Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd, on Friday announced the expansion of its strategic collaboration with Civica, Inc. to include a new Insulin Glargine product aimed at improving the availability of high-quality, affordable insulins for patients in the United States. Under the multi-year agreement, Biocon…